

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

NOTICE OF CLASS MEETING OF THE HOLDERS OF DOMESTIC SHARES

NOTICE IS HEREBY GIVEN THAT a class meeting of the holders of domestic invested shares (“**Domestic Shares**”) of nominal value of RMB0.10 each in Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) will be held at 9th Floor, Block A2, Tianda High-Tech Park, No. 80, The 4th Avenue, TEDA, Tianjin, the People’s Republic of China (the “**PRC**”) on Monday, 19 September 2022 at 10:30 a.m. (or immediately after the conclusion or adjournment of the extraordinary general meeting of the holders of Domestic Shares and foreign invested shares (“**H Shares**”) of nominal value of RMB0.10 each of the Company which has been convened to be held at the same place and on the same date) to consider and, if thought fit, pass the following resolutions:

SPECIAL RESOLUTIONS

1. “**THAT**

- (a) the H shares subscription agreements dated 18 June 2022 (the “**H Shares Subscription Agreements**”) entered into between the Company and Bright Fortune Enterprises Development Limited, Hong Kong Kayui Investment Holdings Limited and Chiu Kwok Shing, Vincent (collectively, the “**H Shares Subscribers**”) in relation to the subscription of not more than 200,000,000 new H shares of RMB0.10 each (the “**Subscription H Shares**”) in the share capital of the Company by the H Shares Subscribers, a copy of each of the H Shares Subscription Agreements is produced to the meeting as marked “A” and signed by the Chairman of the meeting for the purpose of identification, and all the transactions contemplated under the H Shares Subscription Agreements be and is hereby approved, confirmed and ratified, and that the board of directors of the Company (the “**Board**”) be and is hereby authorized to make changes or amendments to the H Shares Subscription Agreements as it may in its absolute discretion think fit;

- (b) the Board be and is hereby granted a specific mandate to allot and issue any of the Subscription H Shares pursuant to the H Shares Subscription Agreements (the “**H Shares Specific Mandate**”); and authorized to register the increase in registered capital in accordance with the actual increase of capital in relation to the issue of any of the Subscription H Shares with the relevant authorities and to make all necessary filings with the relevant PRC, Hong Kong and/or other authorities; and
- (c) the Board be and is hereby authorized to implement and take all steps and to do any and all acts and things as may be necessary or desirable to give effect to and/or to complete the H Shares Subscription Agreements and the issue of Subscription H Shares under the H Shares Specific Mandate; and to sign and execute any other documents or to do any other matters incidental thereto and/or as contemplated thereunder.”

2. “**THAT**

- (a) the domestic shares subscription agreements dated 18 June 2022 (the “**Domestic Shares Subscription Agreements**”) entered into between the Company and 17 subscribers (collectively, the “**Domestic Shares Subscribers**”) in relation to the subscription of not more than 2,800,000,000 new domestic shares of RMB0.10 each (the “**Subscription Domestic Shares**”) in the share capital of the Company by the Domestic Shares Subscribers, a copy of each of the Domestic Shares Subscription Agreements is produced to the meeting as marked “B” and signed by the Chairman of the meeting for the purpose of identification, and all the transactions contemplated under the Domestic Shares Subscription Agreements be and is hereby approved, confirmed and ratified, and that the Board be and is hereby authorized to make changes or amendments to the Domestic Shares Subscription Agreement as it may in its absolute discretion think fit;
- (b) the Board be and is hereby granted a specific mandate to allot and issue any of the Subscription Domestic Shares pursuant to the Domestic Shares Subscription Agreements (the “**Domestic Shares Specific Mandate**”); and authorized to register the increase in registered capital in accordance with the actual increase of capital in relation to the issue of any of the Subscription Domestic Shares with the relevant authorities and to make all necessary filings with the relevant PRC, Hong Kong and/or other authorities; and

(c) the Board be and is hereby authorized to implement and take all steps and to do any and all acts and things as may be necessary or desirable to give effect to and/or to complete the Domestic Shares Subscription Agreements and the issue of any of the Subscription Domestic Shares under the Domestic Shares Specific Mandate; and to sign and execute any other documents or to do any other matters incidental thereto and/or as contemplated thereunder.”

3. To transact any other business.

Yours faithfully
For and on behalf of the Board of
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC

4 August 2022

Notes:

1. Any shareholders of the Company entitled to attend and vote at the meeting mentioned above is entitled to appoint one or more proxies to attend and vote at the meeting on his/her/its behalf in accordance with the articles of association of the Company. A proxy needs not be a shareholder of the Company.
2. In order to be valid, the proxy form of the holder of Domestic Shares and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at the registered address of the Company not less than 24 hours before the time for holding the meeting or any adjourned meeting.
3. Shareholders of the Company or their proxies shall produce documents of their proof of identity when attending the meeting.
4. The register of the shareholders of the Company will be closed from Saturday, 20 August 2022 to Monday, 19 September 2022 (both days inclusive), during which no transfer of shares will be registered.
5. Shareholders of the Company who intend to attend the meeting mentioned above should complete and deliver to the Company's Registered Office the enclosed reply slip by Tuesday, 30 August 2022. Further details are set out in the reply slip and explanation thereto.
6. Completion and delivery of the proxy form will not preclude a member from attending and voting in person at the meeting if the member so desires and has delivered a valid reply slip for class meeting of the holders of Domestic Shares, and in such event, the proxy form shall be deemed to be revoked.
7. The address of the Company's Registered Office and the contact details of the Company are as follows:

No. 12 Tai Hua Road, The 5th Avenue, TEDA, Tianjin, the PRC
Fax No.: (8622) 5981 6909

As at the date of this announcement, the executive directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.